farmacovigilância abr 2015

8/19/2019 Farmacovigilância Abr 2015

1/61

"#$%#&'()*)+,-&)#.!"##$%$&$'(')# ) &$+$,(-.)# '(

+"/$,"0$1(-2" ') 0)(-.)# ('3)0#(#

Maria Helena Seabra Soares de BrittoProfessora Associada DEFAR/UFMA

ABEF

FAIMER 2010

[email protected]

/0$01)-#2 3)#4$)+ 50 6789


2/61

:)1/;$)&' 0 5010-('+()%0-/'

• 4567 8 469: (;;?@A9 +BCDA9? D9 #9ED< FGH(IJ K


3/61

4:


4/61

• 0


5/61

'


6/61

$#% < =>#-5' # $0#?@' # >%%05)%0-/' < -'&)(# 0 -@'A

)-/0-&)'-#+ 0 '&'$$0 -#1 5'101-'$%#+%0-/0 >1#5#1 -' :'%0% 3#$#

3$'")+#B)#2 5)#*-;1/)&'2 /0$#3)# 5#

5'0-?# '> 3#$# # %'5)")?@' 50">-?C01 ")1)'+;*)


7/61

•

R !KR[


8/61

•

( AD@A9 D< bB< M


9/61

&'-&0)/'

( m 9 K = 9 M RU A ^ A ? a C M A 9 @ B = M RC [ B C V R D <OKRM


10/61

"BVKR; OKRDBVR; bB< OKRU9U


11/61

" R>[


12/61

:0B)1/0 >1' $#&)'-#+ =>#-5' '1 3#&)0-/01$0&040% %05)%0-/'1 #3$'3$)#5'1 3#$#

1>#1 -0&011)5#501 &+D-) 0% 5'101

#50=>#5#1 E1 1>#1 3#$/)&>+#$)5#501)-5)()5>#)12 3'$ 30$D'5' 50 /0%3'

-0&011F$)' 0 &'% 4#)B' &>1/' 3#$# 0+01 01># &'%>-)5#50G

89:;"? @A:B>?C D9E


13/61

#QR ;[


14/61

/9 OKNYM9 D9 m9K=9MRUA^A?aCMA9J ;QR A=ORKV9CV@= 9;

bB


15/61

)%3'$/,-&)# !9K9 B= CRUR =


16/61

( ACDE;VKA9 S9K=9M`BYM9 V


17/61

•

1)-#+ < # )-"'$%#?@' -'/)")# 1'4$03'11D(0+ $0+#?@' >1#+ 0-/$0 >%

0(0-/' #5(0$1' 0 >% %05)%0-/'210-5' =>0 /#+ $0+#?@' < 501&'-:0&)5#'> "') 5'&>%0-/#5# 3$0()#%0-/02 50

"'$%# )-&'%3+0/#G

• -'$%#+%0-/02 %#)1 50 >%# H-)

-'/)")?@' < -0&011F$)# 3#$# *0$#$ >%1)-#+2 5030-50-5' 5# *$#()5#50 5'

0(0-/' 0 5# =>#+)5#50 5# )-"'$%#?@'G


18/61

u

" CE=


19/61

:#$%'-)I#?@' < >% /0$%' >/)+)+)I#5' 3'$ >%

3$'J0/' )-/)/>+#5'. K&'-"0$L-&)#)-/0$-#&)'-#+ 1'4$0 :#$%'-)I#?@' 50

0B)*L-&)#1 /%#-'2 =>0 $0H-0 #1#>/'$)5#501 $0*>+#/;$)#1 5# 0>$'3#2 5' J#3@'0 5'1 01/#5'1 >-)5'12 40% &'%' 0130&)#+)1/#1

5# )-5H1/$)# "#$%#&L>/) 5#1 /$L1 $0*)C013#$# 5)1&>/)$ #130&/'1 &)0-/D")&'1 0 //'1:


20/61

(


21/61

•

( =RCAVRKAZ9PQR D9 ;


22/61

•

);VBDR; S9K=9MRK< R; MB;VR; DR; ;


23/61

3'/0-&)#+ &'%' 5)1&)3+)-# 0 0% 3M5

HN VK`; 9>RKD9^


24/61

•

( ;


25/61

e: o9O9MAV9PQRh

•

/9 M9O9MAV9PQR D< OKRL;;ARC9A; D9 ;9ED


26/61

!RKV9CVRJ 9 =RCAVRKAZ9PQR D9 ;


27/61

7: (M


28/61

'


29/61

"; M


30/61

$050 4$#1)+0)$# 50 &0-/$'1 50 )-"'$%#?C011'4$0 %05)%0-/'1 N$04$#&)%O2 &$)#5# 3'$

%0)' 5# 3'$/#$)# %)-)1/0$)#+ N%1O -P 6GQRS

50 678T /0% ' '4J0/)(' 50 &''$50-#$ >%#$050 50 &0-/$'1 0 10$()?'1 50 )-"'$%#?C01

1'4$0 %05)%0-/'1 0 &'-1'+)5#$ '3'/0-&)#+ &)0-/D")&' ('+/#5' E 3$'5>?@' 0

5)">1@' 5# )-"'$%#?@' 1'4$0%05)%0-/'1 0 3$'5>/'1 3#$# 1#H50G


31/61

( ;


32/61

( ;RMA


33/61

u

" O


34/61

• ( 9BVR=


35/61

( DA;MAO?AC9 D9 S9K=9MRUA^A?aCMA9 D


36/61

K301=>)1# 0 5010-('+()%0-/'K -'$%#+%0-/0 10$0"0$0 # #/)()5#501 50 +'-*' 3$#I' 0U'> '$)0-/#5#1

#' ">/>$'2 $0+#&)'-#5#1 # &)L-&)# '> /0&-'+'*)#2>1#-5' /0 :#J# $01>+/#5'1 3$% 40-0"D&)' &'%0$&)#+G

=>#+=>0$ 0%3$01# =>0 )-(01/0 %#)1 50 89V 5' 10>'$?#%0-/' 0% 301=>)1# 0 5010-('+()%0-/' N3M5O

*#-:# $03>/#?@' 50 10$ >%# 0%3$01# 50 #+/#/0&-'+'*)#G %>)/#1 0%3$01#1 501/# /0*'$)# 1@' 5'$#%' 50 %05)%0-/'12 &'%' # %0$&W 0 # -'(#$/)1G


37/61

#XYZ[\] ^\] _`a\] b`cd`ce_`c\] fZa dga`aha[ i\]ed bdeajhc\Xb\`\ 3M5 a[ "\`[\hdicYcXkjhc\2 j\ a]ga`\ j\hcdj\X dZ

cjea`j\hcdj\Xh

4:$D


38/61

k: oR=BCAM9PQRh

'


39/61

#3+))+)5#50 3#$# /'5'1 '1 3$'")11)'-#)1

5# 1#H50 • "KA^AC9?=


40/61

•

"CD< bB


41/61

•

x R O9MA


42/61

m9VR A=ORKV9CV< @ R K


43/61


44/61

( '


45/61

• ( ACDE;VKA9 S9K=9M`BYM9 D?AMR < MR= R;

OKRL;;ARC9A; D9 ;9ED


46/61

)%3#&/' 3'1)/)(' -' 40%A01/#$ 5'1 >1>F$)'1

0 -# 1#H50 &'+0/)(#

( M


47/61

'] b`cjhlbcd] ^\ ha`mnh\opd j\ cj^q]e`c\ g\`[\hrZmh\ cjhXZa[.

• MB=OKA=


48/61

• 9K=9Z


49/61

( =RCAVRKAZ9PQR D9 ;


50/61

• (?^BC; ^KBOR; OROB?9MARC9A; FMKA9CP9;J ADR;R;J ^


51/61

u " B;R D< =


52/61

*`\jâ] â]\nd] \ ]aà[ ajgàje\^d] baXd] b`dY`\[\] â

g\`[\hdicYcXkjhc\28G *Xds\Xct\opd:

" B;R D< =


53/61

TG #[bXc\opd ^d cjea`a]]a hd[ \ ]aYZ`\jo\"


54/61

RG 1\q^a bqsXch\ Q)# h`a]hc[ajed ahdjv[chd

^\ cj^q]e`c\ g\`[\hrZmh\G

!RD< ]9U?


55/61

9G %djced`ct\opd ^a ^aea`[cj\^d] b`d^Zed]:

HN 9 MRCUAMPQR


56/61

SG #meZ^a] a ba`haboua] fZ\jed \d] sajawhcd] a ^\jd]:

);;9; V


57/61

xG $a]ZXe\^d] a c[b\hed:

}BCV9=


58/61

-'/)")?@' •

(; V


59/61


60/61

,RDR; R; OKRL;;ARC9A; D< ;9ED< D


61/61

farmacovigilância abr 2015

Documents